HBV + C295 ISS-PMXB VACCINE IN BABOONS

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本实验的目的是评估由C295-PMXB与HBV表面抗原联合组成的新制剂的剂量反应。本实验将有助于确定C295-PMXB提高成年狒狒HBV抗原免疫原性的最佳剂量。试验分为4组，每组5只。本实验将有助于确定C295 ISS-PMXB是否能增强狒狒对HBV表面抗原的免疫应答，以及C295 ISS-PMXB增强狒狒免疫应答的最佳剂量。这种新的HBV疫苗（HBV+ C295 ISS-PMXB）可能对社会有益，因为它可以改善对HBV表面抗原的反应，特别是对目前批准的乙型肝炎疫苗反应不良的人。C295 ISS-PMXB配方(1000 ？g C295)先前已在狒狒中与Prevnar疫苗联合试验（正在进行的研究952-PC-0）。然而，C295 ISS-PMXB制剂与HBV疫苗抗原联合从未在狒狒中进行过试验。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objective of this experiment is to assess the dose response of a new formulation consisting of C295-PMXB in combination with HBV surface antigen. This experiment will help determine the optimal dose of C295-PMXB for increased immunogenicity of HBV antigen in adult baboons. This study will consist of 4 groups of 5 animals per group. This experiment will help determine if C295 ISS-PMXB can enhance the immune response to HBV surface antigen, and the optimal dose of C295 ISS-PMXB for enhanced immune response in baboons. This new HBV vaccine (HBV+ C295 ISS-PMXB) may be beneficial to society, since it could improve responses to HBV surface antigen, especially in poor responders to currently approved hepatitis B vaccines. C295 ISS-PMXB formulation (1000 ?g C295) has been previously tested in baboons in combination with Prevnar vaccine (ongoing study 952-PC-0). However, the C295 ISS-PMXB formulation in combination with HBV vaccine antigen has never been tested in baboons.